FY 1996 Epidemiologic Research Studies of Acquired Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV) Infection
Federal RegisterJun 18, 1996
Ask Donna
What actually matters in this document.
Text
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Announcement Number 625]
FY 1996 Epidemiologic Research Studies of Acquired
Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV)
Infection
Introduction
The Centers for Disease Control and Prevention (CDC) announces the
availability of fiscal year (FY) 1996 funds for a cooperative agreement
program for epidemiologic and behavioral research studies of AIDS and
HIV infection. These include studies to examine factors related to
disease progression of HIV infection in women, mother-to-child HIV
transmission, sexual and needleborne transmission of HIV among drug
users, and the spread of HIV infection in rural and small cities in the
United States. The study of these research areas as they pertain to
racial and ethnic minority populations (defined as Black, Hispanic,
Asian and Pacific Islander, and American Indian) is encouraged because
minorities constitute over 50% of all reported cases of AIDS and
approximately 76% of all women and children with AIDS.
CDC is committed to achieving the health promotion and disease
prevention objectives of Healthy People 2000, a national activity to
reduce morbidity and mortality and improve the quality of life. This
announcement is related to the priority area of HIV Infection. (To
order a copy of ``Healthy People 2000,'' see the section WHERE TO
OBTAIN ADDITIONAL INFORMATION.)
Authority
This program is authorized under Sections 301(a) and 317(k)(2) of
the Public Health Service Act [42 U.S.C. 241(a) and 247b(k)(2)], as
amended. Applicable program regulations are set forth in 42 CFR Part
52, entitled ``Grants for Research Projects.''
Smoke-Free Workplace
CDC strongly encourages all cooperative agreement recipients to
provide a smoke-free workplace and promote the non-use of all tobacco
products. Public Law 103-227, the Pro-Children Act of 1994, prohibits
smoking in certain facilities that receive Federal funds in which
education, library, day care, health care, and early childhood
development services are provided to children. This is consistent with
the PHS mission to protect and advance the physical and mental health
of American people.
Eligible Applicants
Eligible applicants include all public and private, nonprofit and
for-profit organizations and governments and their agencies. Thus,
universities, colleges, research institutions, hospitals, and other
public and private organizations, State and local governments or their
bona fide agents, federally recognized Indian tribal governments,
Indian tribes or Indian tribal organizations, and small, minority- or
women-owned businesses are eligible to apply.
Note: Organizations described in section 501(c)(4) of the
Internal Revenue Code of 1986 that engage in lobbying are not
eligible to receive Federal grant/cooperative agreement funds.
Availability of Funds
Approximately $6,900,000 will be available in FY 1996 to fund
approximately 16 awards. It is expected that the average new award will
be approximately $300,000 and that the average continuation award will
be $500,000, ranging from $100,000 to $1,000,000. It is expected that
approximately 3 new and 13 competing renewal awards will be made and
that awards will begin on or about September 30, 1996. Awards will be
funded for a 12-month budget period within a project period of up to 5
years. Funding estimates may vary and are subject to change.
Continuation awards within the project period will be made on the basis
of satisfactory programmatic progress and the availability of funds.
Purpose
The purpose of these awards is to help support researchers in the
conduct of HIV-related epidemiologic and behavioral research studies.
These include studies to examine factors related to disease progression
of HIV infection in women, mother-to-child HIV transmission, sexual and
needleborne transmission of HIV among drug users, and the spread of HIV
infection in small cities and rural areas in the United States. The
study of these research areas as they pertain to minority populations
are of special interest.
Research Issues
Four research issues of programmatic interest to the health care
community and to CDC for FY 1996 are listed below and are considered of
significant importance in gaining a greater understanding of the
epidemiology of AIDS and HIV infection. However, applications submitted
by organizations that examine additional important HIV-related
epidemiologic research issues will also be accepted and considered for
funding.
Applicants addressing the same research issue should be willing to
participate in collaborative studies with other CDC-sponsored
researchers, including the use of common data collection instruments,
specimen collection protocols, and data management procedures.
Applicants are required to identify their proposed research issue on
line 1 of the face page of the application if the PHS-398 is used, or
Block 11 of the face page if the PHS-5161-1 is used (for more
information on the forms to use, see the section APPLICATION SUBMISSION
AND DEADLINE).
1. Studies of HIV Disease Progression in Women
Studies should be designed to identify, enroll, and prospectively
follow women who are HIV-infected and demographically similar women who
are not HIV-infected but who have demonstrable risk for HIV infection
so that the biologic, behavioral, and psychosocial determinants and
correlates of HIV disease progression
[[Page 30900]]
and other health outcomes can be assessed. Preference will be given to
sites (1) where at least 200 HIV-infected and 100 HIV-uninfected women
are already being systematically followed, (2) at which behavioral
scientists are part of the research team, and (3) at which the
applicant or its documented collaborative partners have the ability to
perform virologic and immunologic assays. Applicants must demonstrate
that they can provide adequate rates of follow-up, including collection
of laboratory specimens, tracking and abstraction of medical records,
and determination of causes of deaths. Applicants must be willing to
participate in collaborative studies with other CDC-sponsored women's
HIV disease progression projects, including the use of common data
collection instruments, specimen collection protocols, and data
management procedures. Applicants must demonstrate cost-efficient local
data management and statistical capability.
2. Mother-to-Child HIV Transmission Studies
Studies should be designed to identify HIV-infected women during
pregnancy or at delivery and enroll the women and their infants in a
prospective follow-up study to examine factors related to mother-to-
child HIV transmission, early diagnosis of infant infection, and
disease progression in children. Studies designed to examine the effect
of interventions such as zidovudine use to prevent mother-to-child HIV
transmission are of particular interest. Preference will be given to
applicants with studies in which mother-infant pairs are already being
systematically identified and followed, and which have the ability to
perform virologic and immunologic assays. Applicants must demonstrate
that they can provide adequate rates of follow-up of both mothers and
infants, including collection of laboratory specimens at periodic
intervals (particularly within the first 48 hours of birth and during
the first 6 months of life), and long-term follow-up of infants,
including those placed in foster care. Applicants must be willing to
participate in collaborative studies with other CDC-sponsored mother-
to-child HIV transmission projects, including use of common data
collection instruments and study design where warranted. Applicants
must demonstrate cost-efficient data management, laboratory testing,
and statistical capability or provide explicit plans for data
management by CDC or an outside group. Applicants must demonstrate the
ability to enroll and follow at least 30 HIV-positive mother-infant
pairs per year.
3. Sexual and Needleborne Transmission of HIV Among Drug Users
Study proposals are solicited that address HIV infection in young
drug-abusing populations that are recruited on the street and not
routinely seen in clinics, hospitals, or similar institutional
settings. The purpose of such studies will be to address issues
important to the sexual, needleborne, and injection paraphernalia
related transmission of HIV and settings that may contribute to HIV
infection among drug users who are not seen in the usual medical and
drug-treatment facilities. Preference will be given to projects that
involve community outreach to enroll recently initiated drug users for
interview and examination and that focus on inner-city or rural areas
where drug use among young adults is prevalent.
Examples of worthwhile proposals are HIV seroincidence cohorts that
describe initiating practices of injection and risks for young adults;
current sources, acquisition, and cleaning and disposal of needles and
syringes; issues of violence as they relate to drug use and the impact
on individual, family and community; social networks including contacts
and community dynamics that affect HIV incidence. Other related aspects
of incidence and management of infectious complications of drug use,
including skin and respiratory infections that could be altered by HIV
immune suppression, and their possible impact on the progression of HIV
infection. Applicants should demonstrate their ability to access young
injection drug-using populations not currently in drug treatment,
interview and examine them in a confidential manner, and provide or
link study participants to appropriate medical, drug-treatment and
other services. Applicants for studies of these difficult-to-reach
populations should demonstrate their ability to provide new insights
into the epidemiology of HIV infection in injecting drug users and not
duplicate other projects; possess cost-effective data management and
statistical capabilities, or provide specific plans for management of
data; and participate collaboratively in a multisite study with other
researchers in the development, implementation, and analysis of data
from the proposed study.
4. HIV Infection in Small Cities and Rural Areas
Studies should be designed to identify, interview, and learn more
about HIV-infected persons who live in rural and small cities (small
cities and rural areas outside metropolitan statistical areas of more
than 500,000) such as their (1) modes of exposure to HIV, (2) substance
abuse, (3) travel/migration patterns, (4) health care seeking
behaviors, (5) barriers to care, and (6) sexually transmitted diseases.
Preference will be given to studies that address the following
questions. What specific behaviors (e.g., sexual and substance abuse)
are related to infection of persons residing in these areas? Did
persons from these areas become infected in their current areas of
residence or during travel or residences in large metropolitan areas?
What are the barriers to care specific to HIV-infected persons living
in small cities and rural areas? What health care sites (e.g., STD and
family planning clinics) did the patient visit during and before the
estimated time period of infection, and what HIV prevention messages
and services were offered and received?
Applicants must demonstrate the ability to enroll and follow at
least 50 HIV-infected patients residing in small cities and rural
areas. Applicants must be willing to participate collaboratively in a
multi-site study with other researchers in the development,
implementation, and analysis of data from the proposed study.
Applicants are expected to determine proper distribution of
participants by sex, race, and ethnicity for their topic of study and
to state clearly in the application the composition of the proposed
study population. If women, racial, or ethnic minorities are not
included in the proposed study, applicants must justify their
exclusion.
Program Requirements
Under this cooperative agreement program, CDC will assist the
researcher in conducting the epidemiologic research of AIDS and HIV
infection described in the PURPOSE section of this announcement.
In conducting activities to achieve the purpose of this program,
the recipient shall be responsible for the activities listed under
subparagraph 1., below, and CDC shall be responsible for the activities
listed under subparagraph 2., below:
1. Recipient Activities
Applicants addressing the same research issue must be willing to
participate in collaborative studies with other CDC-sponsored
researchers, including the use of common data collection instruments,
specimen collection protocols, and data management procedures.
[[Page 30901]]
a. Meet with other funded grantees and develop the research study
protocol and the interview instrument.
b. Identify, recruit, obtain informed consent from, and enroll an
adequate number of study participants as determined by the study
protocol and the program requirements.
c. Continue to follow study participants as determined by the study
protocol.
d. Establish procedures to maintain the rights and confidentiality
of all study participants.
e. Perform laboratory tests (when appropriate) and data analysis as
determined in the study protocol.
f. Collaborate and share data and specimens (when appropriate) with
other collaborators to answer specific research questions.
g. Conduct data analysis with all collaborators as well as present
research findings subject to the provisions of the following section,
CDC Activities.
2. CDC Activities
a. Provide technical assistance in the design and conduct of the
research.
b. Provide technical guidance in the development of study
protocols, consent forms and questionnaires.
c. Assist in designing a data management system.
d. Perform selected laboratory tests.
e. Coordinate research activities among the different sites.
f. Participate in the analysis of research information and the
presentation of research findings.
Evaluation Criteria
All applications will be reviewed according to the same criteria;
however, applicants will be ranked on a scale of 200 maximum points
according to the four research issues listed above and a fifth category
for all other HIV-related epidemiologic studies. All applicants must
state which research category they are addressing. Applications should
demonstrate the applicant's ability to address the research problem in
a collaborative manner with CDC. Applications will be reviewed and
evaluated based on the evidence submitted, which specifically describes
the applicant's abilities to meet the following criteria:
1. The inclusion of a detailed review of the scientific literature
pertinent to the study being proposed and specific research questions
or hypotheses that will guide the research; (25 points)
2. The originality and need for the proposed research, the extent
to which it does not replicate past or present research efforts, and
how findings will be used to guide prevention and control efforts; (25
points)
3. The quality of the plans to develop and implement the study
describing how study participants (including racial and ethnic minority
populations) will be identified, enrolled, tested and followed; (25
points)
4. The ability to enroll and follow an adequate number of eligible
study participants to ensure proper conduct of the study. This includes
demonstration of the availability of HIV-infected potential study
participants and the experience of the investigator in enrolling and
following such persons in a culturally and linguistically appropriate
manner; the degree to which the applicant has met the CDC Policy
requirements regarding the inclusion of women, ethnic, and racial
groups in the proposed research. This includes:
a. The proposed plan for the inclusion of both sexes and racial and
ethnic minority populations for appropriate representation;
b. The proposed justification when representation is limited or
absent;
c. A statement as to whether the design of the study is adequate to
measure differences when warranted;
d. A statement as to whether the plans for recruitment and outreach
for study participants include the process of establishing partnerships
with community(ies) and recognition of mutual benefits will be
documented; (25 points)
5. The applicant's understanding of the research objectives and the
ability, willingness, and need to collaborate with CDC and researchers
from other study sites in study design and analysis, including use of
common forms, and sharing of specimens (when appropriate) and data; (25
points)
6. The applicant's current experience in AIDS and HIV epidemiologic
or behavioral research and how it will be applied to achieving the
objectives of the study (letters of support from cooperating
organizations that demonstrate the nature and extent of such
cooperation should be included); (20 points)
7. The comprehensiveness of the plan to protect the rights and
confidentiality of all participants; (20 points)
8. Availability of qualified and experienced personnel with
realistic and sufficient percentage-time commitments; clarity of the
described duties and responsibilities of project personnel; adequacy of
the facilities, equipment, and plans for the administration of the
project, including project oversight and data management; (20 points)
9. A comprehensive schedule for accomplishing the activities of the
research and an evaluation plan that identifies methods and instruments
for evaluating progress in designing and implementing the research
objectives. (15 points)
10. Other (Not Scored).
(1) Budget
The budget will be reviewed to determine the extent to which it is
reasonable, clearly justified, consistent with the intended use of
funds, and allowable. All budget categories should be itemized.
(2) Human Subjects
Whether or not exempt from the DHHS regulations, are procedures
adequate for the protection of human subjects? Recommendations on the
adequacy of protections include: (a) protections appear adequate and
there are no comments to make or concerns to raise, or (b) protections
appear adequate, but there are comments regarding the protocol, or (c)
protections appear inadequate and the Objective Review Group (ORG) has
concerns related to human subjects; or (d) disapproval of the
application is recommended because the research risks are sufficiently
serious and protection against the risks are inadequate as to make the
entire application unacceptable.
Funding Preferences
Priority will be given to competing continuation applications from
satisfactorily performing projects over applications for projects not
already receiving support under the program. Projects will be awarded
so that the composite of projects represents the geographic and
demographic characteristics of the HIV-infected population.
Executive Order 12372 Review
Applications are not subject to review under Executive Order 12372,
Intergovernmental Review of Federal Programs.
Public Health System Reporting Requirements
This program is not subject to the Public Health System Reporting
Requirements.
Catalog of Federal Domestic Assistance Number
The Catalog of Federal Domestic Assistance Number is 93.943,
Epidemiologic Research Studies of Acquired Immunodeficiency Syndrome
(AIDS) and Human Immunodeficiency Virus (HIV) Infection in Selected
Population Groups.
[[Page 30902]]
Other Requirements
1. Paperwork Reduction Act
Projects that involve the collection of information from 10 or more
individuals and funded by cooperative agreement will be subject to
review by the Office of Management and Budget (OMB) under the Paperwork
Reduction Act.
2. Human Subjects
This program involves research on human subjects. Therefore, all
applicants must comply with the Department of Health and Human Services
Regulations, 45 CFR Part 46, regarding the protection of human
subjects. Assurance must be provided to demonstrate that the project or
activity will be subject to initial and continuing review by an
appropriate institutional review committee. The applicant will be
responsible for providing assurance in accordance with the appropriate
guidelines and form provided in the application kit.
In addition to other applicable committees, Indian Health Service
(IHS) institutional review committees also must review the project if
any component of IHS will be involved with or support the research. If
any American Indian community is involved, its tribal government must
also approve that portion of the project applicable to it.
3. HIV/AIDS Requirements
Recipients must comply with the document entitled Content of AIDS-
Related Written Materials, Pictorials, Audiovisuals, Questionnaires,
Survey Instruments, and Educational Sessions (June 1992) (a copy is in
the application kit). To meet the requirements for a program review
panel, recipients are encouraged to use an existing program review
panel, such as the one created by the State health department's HIV/
AIDS prevention program. If the recipient forms its own program review
panel, at least one member must be an employee (or a designated
representative) of a State or local health department. The names of the
review panel members must be listed on the Assurance of Compliance form
CDC 0.1113, which is also included in the application kit. The
recipient must submit the program review panel's report that indicates
all materials have been reviewed and approved.
4. Patient Care
Applicants should provide assurance that all HIV-infected patients
enrolled in their studies will be linked to an appropriate local HIV
care system that can address their specific needs such as medical care,
counseling, social services, and therapy. Details of the HIV care
system should be provided, describing how patients will be linked to
the system. Funds will not be made available to support the provision
of direct care for study participants.
5. Women, Racial and Ethnic Minorities
It is the policy of the CDC to ensure that individuals of both
sexes and the various racial and ethnic groups will be included in CDC-
supported research projects involving human subjects, whenever feasible
and appropriate. Racial and ethnic groups are those defined in OMB
Directive No. 15 and include American Indian, Alaskan Native, Asian,
Pacific Islander, Black and Hispanic. Applicants shall ensure that
women, racial and ethnic minority populations are appropriately
represented in applications for research involving human subjects.
Where clear and compelling rationale exist that inclusion is
inappropriate or not feasible, this situation must be explained as part
of the application. This policy does not apply to research studies when
the investigator cannot control the race, ethnicity and/or sex of
subjects. Further guidance to this policy is contained in the Federal
Register, Vol. 60, No. 179, Friday, September 15, 1995, pages 47947-
47951 (a copy is included in the application kit).
Application Submission and Deadline
The original and five copies of the completed application packet
PHS 398 (Revised 5/95, OMB No. 0925-0001) must be submitted to Van
Malone, Grants Management Officer (ATTN: Kevin Moore), Grants
Management Branch, Procurement and Grants Office (625), Centers for
Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE.,
Room 320, Mail Stop E-15, Atlanta, Georgia 30305, on or before August
2, 1996. States and local governments may use Form PHS-5161-1 (Revised
7/92, OMB No. 0937-0189); however, Form PHS-398 is preferred. If using
Form PHS-5161-1, submit an original and two copies to the address
stated above.
1. Deadline
Applications shall be considered as meeting the deadline if they
are either:
a. Received on or before the stated deadline date; or
b. Sent on or before the deadline date and received in time for
submission to the independent review group. (Applicants must request a
legibly dated U.S. Postal Service postmark or obtain a legibly dated
receipt from a commercial carrier or U.S. Postal Service. Private
metered postmarks shall not be accepted as proof of timely mailing.)
2. Late Applications
Applications that do not meet the criteria in 1.a. or 1.b. above
are considered late applications. Late applications will not be
considered in the current competition and will be returned to the
applicant.
Where to Obtain Additional Information
A complete program description, information on application
procedures, an application package, and business management technical
assistance may be obtained from Kevin Moore, Grants Management
Specialist, Grants Management Branch, Procurement and Grants Office,
Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry
Road, NE., Room 320, Mail Stop E-15, Atlanta, Georgia 30305, telephone
(404) 842-6550, E-mail address [email protected]. The
announcement will be available on one of two Internet sites on the
publication date: CDC's home page at http://www.cdc.gov, or at the
Government Printing Office home page (including free access to the
Federal Register) at http://www.access.gpo.gov.
Programmatic technical assistance may be obtained from Jeff Efird,
Division of HIV/AIDS Prevention, National Center for HIV, STD, TB
Prevention, Centers for Disease Control and Prevention (CDC), 1600
Clifton Road, NE., Mail Stop E-45, Atlanta, Georgia 30333, telephone
(404) 639-6130. Eligible applicants are encouraged to call before
developing and submitting their application. Please refer to
Announcement Number 625 when requesting information.
Potential applicants may obtain a copy of ``Healthy People 2000''
(Full Report, Stock No. 017-001-00474-0) or ``Healthy People 2000''
(Summary report, Stock No. 017-001-00473-1) referenced in the
Introduction from the Superintendent of Documents, Government Printing
Office, Washington, DC 20402-9325, telephone (202) 512-1800.
Dated: June 11, 1996.
Joseph R. Carter,
Acting Associate Director for Management and Operations, Centers for
Disease Control and Prevention (CDC).
[FR Doc. 96-15379 Filed 6-17-96; 8:45 am]
BILLING CODE 4163-18-P
This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.